MIM
HUMA icon

MTM Investment Management’s Humacyte HUMA Stock Holding History

MTM Investment Management’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$858 Hold
1,100
– – ﹤0.01% 673
2026
Q1 		$667 Hold
1,100
– – ﹤0.01% 674
2025
Q4 		$1.06K Buy
+1,100
New +$1.56K ﹤0.01% 666

Other funds holding HUMA

AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

MTM Investment Management's HUMA Position: Q2 2026 in Review

MTM Investment Management held its Humacyte (HUMA) position steady in Q2 2026 at 1,100 shares worth $858. The position accounts for ﹤0.01% of the portfolio, ranked #673.

MTM Investment Management first reported a position in HUMA in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.06K in Q4 2025. 163 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

  • MTM Investment Management held 1,100 shares of Humacyte worth $858 as of Q2 2026.
  • MTM Investment Management left its Humacyte share count unchanged in Q2 2026.
  • Humacyte made up ﹤0.01% of MTM Investment Management's portfolio in Q2 2026, its #673 holding.
  • MTM Investment Management first reported a position in Humacyte in Q4 2025 and has held it in 3 quarters since.
  • MTM Investment Management's Humacyte position peaked at $1.06K in Q4 2025.
  • 163 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on MTM Investment Management's 13F filing for Q2 2026, filed 3 Aug 2026.